Brentuximab Vedotin Plus Bendamustine in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Meta-Analysis

被引：1
|
作者：
Abdelgawad, Hussien Ahmed H. [1 ,2 ]
Belal, Mohamed Mohamed [3 ]
Bashir, Mohamed Nabih [3 ]
Aboeldahab, Heba [4 ,5 ]
Eshun, Francis [1 ,2 ]
Otto, Mario [1 ,2 ]
Henry, Michael [1 ,2 ]
机构：
[1] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA
[2] Phoenix Childrens Hosp, Ctr Canc & Blood Disorders, Phoenix, AZ USA
[3] Alexandria Univ, Fac Med, Alexandria, Egypt
[4] El Gomhoria Gen Hosp, Clin Res Dept, Alexandria, Egypt
[5] Alexandria Univ, Med Res Inst, Biomed Informat & Med Stat Dept, Alexandria, Egypt
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187466
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma Who Are Relapsed or Refractory After Frontline Therapy
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (02) : 8 - 10
  • [22] Brentuximab Vedotin in Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma: A Retrospective Analysis on 23 Paediatric Patients or Young Adults
    Vinti, Luciana
    Locatelli, Franco
    Merli, Pietro
    Parasole, Rosanna
    Buffardi, Salvatore
    Pillon, Marta
    Strocchio, Luisa
    Girardi, Katia
    BLOOD, 2017, 130
  • [23] BRENTUXIMAB VEDOTIN PLUS VIGEPP CHEMOTHERAPY FOR RELAPSED/REFRACTORY ADOLESCENT HODGKIN LYMPHOMA
    Tsaplina, N.
    Valiev, T.
    LEUKEMIA RESEARCH, 2022, 121 : S60 - S60
  • [24] Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma
    Chen, Runzhe
    Chen, Baoan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1729 - 1733
  • [25] Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
    LaCasce, Ann S.
    Bociek, R. Gregory
    Sawas, Ahmed
    Caimi, Paolo
    Agura, Edward
    Matous, Jeffrey
    Ansell, Stephen M.
    Crosswell, Howland E.
    Islas-Ohlmayer, Miguel
    Behler, Caroline
    Cheung, Eric
    Forero-Torres, Andres
    Vose, Julie
    O'Connor, Owen A.
    Josephson, Neil
    Wang, Yinghui
    Advani, Ranjana
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (03) : E86 - E90
  • [26] Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Palmer, Joycelynne M.
    Herrera, Alex Francisco
    Armenian, Saro H.
    Mei, Matthew
    Popplewell, Leslie
    Fueger, Abbey
    Qasim, Imran
    Stiller, Tracy
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2017, 130
  • [27] Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
    Kambhampati, Swetha
    Mei, Matthew
    Chen, Lu
    Puverel, Sandrine
    Chen, Robert
    Popplewell, Leslie L.
    Nikolaenko, Liana
    Peters, Lacolle
    Armenian, Saro H.
    Kwak, Larry W.
    Rosen, Steve T.
    Forman, Stephen J.
    Herrera, Alex F.
    BLOOD, 2022, 140 : 9418 - 9419
  • [28] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
    Salihoglu, A.
    Elverdi, T.
    Karadogan, I.
    Paydas, S.
    Ozdemir, E.
    Erdem, G.
    Karadurmus, N.
    Akyol, G.
    Kaynar, L.
    Yegin, Z. A.
    Sucak, G.
    Ozkocaman, V.
    Topcuoglu, P.
    Ozcan, M.
    Birtas, E.
    Goker, H.
    Baslar, Z.
    Ferhanoglu, B.
    ANNALS OF HEMATOLOGY, 2015, 94 (03) : 415 - 420
  • [29] Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
    Siddiqi, Tanya
    Thomas, Sandra H.
    Chen, Robert
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 79 - 85
  • [30] Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
    Thiruvengadam, Swetha Kambhampati
    Mei, Matthew G.
    Chen, Lu
    Puverel, Sandrine
    Chen, Robert
    Popplewell, Leslie L.
    Nikolaenko, Liana
    Peters, Lacolle
    Armenian, Saro
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10):
12345